0001209191-21-008231.txt : 20210205
0001209191-21-008231.hdr.sgml : 20210205
20210205175043
ACCESSION NUMBER: 0001209191-21-008231
CONFORMED SUBMISSION TYPE: 5
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201231
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Galante Joseph C
CENTRAL INDEX KEY: 0001632384
FILING VALUES:
FORM TYPE: 5
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 21597581
MAIL ADDRESS:
STREET 1: 111 TENTH AVENUE
STREET 2: SUITE 200
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
5
1
doc5.xml
FORM 5 SUBMISSION
X0306
5
2020-12-31
0
0
1
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001632384
Galante Joseph C
2525 WEST END AVENUE
SUITE 950
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2020-10-09
4
L
0
75
3.25
A
27217
D
Common Stock
2020-10-12
4
L
0
75
3.23
A
27292
D
Common Stock
2020-10-13
4
L
0
75
3.21
A
27367
D
Common Stock
2020-10-14
4
L
0
75
3.14
A
27442
D
Common Stock
2020-10-15
4
L
0
75
3.07
A
27517
D
Common Stock
2020-10-16
4
L
0
75
3.07
A
27592
D
Common Stock
2020-10-19
4
L
0
75
3.03
A
27667
D
Common Stock
2020-10-20
4
L
0
75
3.04
A
27742
D
Common Stock
2020-10-21
4
L
0
75
3.04
A
27817
D
Common Stock
2020-10-22
4
L
0
75
3.08
A
27892
D
Common Stock
2020-10-23
4
L
0
75
3.04
A
27967
D
Common Stock
2020-10-26
4
P
0
75
3.02
A
28042
D
Common Stock
2020-10-27
4
P
0
75
3.06
A
28117
D
Common Stock
2020-10-28
4
P
0
75
2.97
A
28192
D
Common Stock
2020-10-29
4
P
0
75
3.02
A
28267
D
Common Stock
2020-10-30
4
P
0
75
2.99
A
28342
D
Common Stock
2020-11-02
4
P
0
75
2.97
A
28417
D
Common Stock
2020-11-03
4
P
0
75
2.99
A
28492
D
Common Stock
2020-11-04
4
P
0
75
3.01
A
28567
D
Common Stock
2020-11-05
4
P
0
75
2.98
A
28642
D
Common Stock
2020-11-06
4
P
0
75
2.99
A
28717
D
Common Stock
2020-11-09
4
P
0
75
3.06
A
28792
D
Common Stock
2020-11-10
4
P
0
75
3.09
A
28867
D
Common Stock
2020-11-11
4
P
0
75
3.12
A
28942
D
Common Stock
2020-11-12
4
P
0
75
3.03
A
29017
D
Common Stock
2020-11-13
4
P
0
75
3.04
A
29092
D
Common Stock
2020-11-16
4
P
0
75
3.05
A
29167
D
Common Stock
2020-11-17
4
P
0
75
2.96
A
29242
D
Common Stock
2020-11-18
4
P
0
75
3.01
A
29317
D
Common Stock
2020-11-19
4
P
0
75
2.98
A
29392
D
The purchases reported in this Form 5 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
Filing 2 of 3
Joseph C. Galante by /s/ Michael Bonner as attorney-in-fact
2021-02-05